The GOLGA2 Knockout HeLa Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout model for studying the GOLGA2 gene, which encodes the cis-Golgi matrix protein GM130. Derived from HeLa human cervical adenocarcinoma cells, this polyclonal population enables robust functional analysis of GM130 deficiency without the selective pressures of clonal isolation, preserving heterogeneous genetic backgrounds typical of cancer cell populations. The knockout disrupts GOLGA2 expression, offering a versatile tool for investigating Golgi-dependent cellular processes.
HeLa cells are an immortalized, HPV18-positive cervical adenocarcinoma line extensively used in biomedical research due to their rapid proliferation, high transfection efficiency, and well-characterized biology. They exhibit active secretory and migratory phenotypes, making them an optimal host for exploring the interplay between Golgi organization, vesicular trafficking, and cell motility. This genetic background provides a clinically relevant context for studying cervical cancer pathogenesis and general cell biological mechanisms.
GM130 functions as a critical structural component of the cis-Golgi, where it scaffolds protein complexes essential for Golgi ribbon maintenance and polarized trafficking. It interacts directly with the tethering factor USO1 (p115) and the GRASP65 protein (GORASP1), facilitating ER-to-Golgi transport and intra-Golgi vesicle dynamics. GM130 activity is tightly regulated by mitotic kinases CDK1 and PLK1, which phosphorylate the protein to promote Golgi disassembly at the onset of mitosis. Additionally, GM130 associates with small GTPases RAB1B and RAB2A, modulating COPI and COPII vesicle budding and fusion through SNARE protein engagement and the TRAPP tethering complex. Downstream, GM130 governs the subcellular distribution of Golgi resident enzymes, the efficiency of constitutive and regulated secretion, and the surface expression of integrins, ultimately influencing cell adhesion and directed migration.
In the HeLa cervical adenocarcinoma model, loss of GM130 triggers Golgi ribbon fragmentation into dispersed ministacks, leading to defective polarized secretion and impaired directional cell migration??processes central to metastatic dissemination. This knockout system thus permits detailed examination of how Golgi structural integrity contributes to invasive behavior, mitotic progression, and the response to cellular stress. It also offers a platform to investigate the molecular underpinnings of Golgi fragmentation-associated pathologies and to explore the role of GM130 in HPV18-positive cervical cancer progression.
These polyclonal knockout cells are suited for a broad range of experimental applications, including Western blotting to verify GM130 depletion, immunofluorescence microscopy to visualize Golgi morphology, and RT-qPCR to measure residual GOLGA2 transcript levels. Functional assays such as scratch-wound migration, Transwell invasion, and protein secretion analyses can be combined with mitotic synchronization to study Golgi fragmentation dynamics. The model further supports co-immunoprecipitation of GM130 binding partners and high-throughput screening of compounds targeting Golgi-mediated pathways. For detailed product information, please contact Ascent Research.
